Effect of Age on Treatment Outcomes in C lostridium difficile Infection
Authors:
- 4 February 2013
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 61 (2) , 222-230
Abstract
Objectives: To determine the effect of advancing age on the clinical outcomes of C lostridium difficile ( CDI ) treatment. Design: Regression modeling of results from two double‐blind randomized multicenter studies on the treatment of primary and first recurrent cases of CDI to examine for effects of age and study drug on outcomes of cure (resolution of diarrhea), recurrence within 4 weeks of completing successful therapy, and cure without recurrence. Setting: Participants were randomized into studies in the U nited S tates, C anada, and E urope. Participants: Nine hundred ninety‐nine individuals with toxin‐positive CDI were randomized to receive vancomycin (125 mg 4 times daily) or fidaxomicin (200 mg twice daily) for 10 days. Measurements: The effect of advancing age in those aged 18 to 40 years and in 10‐year increments thereafter was examined. Results: The model predicts a 17% lower clinical cure, 17% greater recurrence, and 13% lower sustained clinical response by advancing decade than in those younger than 40 ( P < .01 each). Clinical cure was similar in the fidaxomicin and vancomycin treatment groups, although fidaxomicin was associated with a more than 50% lower relative risk for recurrence than vancomycin ( P < .001). Multivariate regression modeling showed that risk factors accounting for poorer outcomes with advancing age include infection with the BI strain type, inpatient status, renal insufficiency, leukocytosis, hypoalbuminemia, and concomitant medication exposure. Conclusion: Measurable and progressive deterioration in CDI treatment outcomes occurred with advancing age in those aged 40 and older, highlighting the need for prevention and treatment strategies. Fidaxomicin treatment was associated with a 60% lower risk of recurrence than vancomycin after adjusting for age, concomitant antibiotics, and C . difficile strain.Keywords
This publication has 41 references indexed in Scilit:
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDIClinical Infectious Diseases, 2012
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent InfectionsClinical Infectious Diseases, 2011
- Relationship between functional ability in older people, immune system status, and intensity of response to CMVAGE, 2011
- Ageing of the human metaorganism: the microbial counterpartAGE, 2011
- Metabolic syndrome, hormones, and maintenance of T cells during agingCurrent Opinion in Immunology, 2010
- The Changing Epidemiology of Clostridium difficile InfectionsClinical Microbiology Reviews, 2010
- Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and CentenariansPLOS ONE, 2010
- Clinical Risk Factors for SevereClostridium difficile–associated DiseaseEmerging Infectious Diseases, 2009
- The Firmicutes/Bacteroidetes ratio of the human microbiota changes with ageBMC Microbiology, 2009
- Comparison of Seven Techniques for Typing International Epidemic Strains of Clostridium difficile : Restriction Endonuclease Analysis, Pulsed-Field Gel Electrophoresis, PCR-Ribotyping, Multilocus Sequence Typing, Multilocus Variable-Number Tandem-Repeat Analysis, Amplified Fragment Length Polymorphism, and Surface Layer Protein A Gene Sequence TypingJournal of Clinical Microbiology, 2008